Global Gastric Cancer Treatment Market - 2025-2033

The global gastric cancer treatment market size reached US$ 5.82 billion in 2024 and is expected to reach US$ 14.66 billion by 2033, growing at a CAGR of 10.9% during the forecast period 2025-2033.

Gastric cancer, also known as stomach cancer, refers to a type of cancer that begins in the cells lining the stomach. It is one of the most common and deadly forms of cancer worldwide, particularly prevalent in East Asia, Europe, and parts of South America. Gastric cancer can develop in any part of the stomach and may spread to other organs, such as the esophagus, pancreas, liver, and lymph nodes.

Gastric cancer primarily originates from the epithelial cells that line the stomach, leading to adenocarcinoma, which is the most common type of gastric cancer (around 90-95% of cases). However, gastric cancer can also include other, rarer forms such as lymphoma (cancer of lymphatic tissue), gastrointestinal stromal tumors (GISTs), and neuroendocrine tumors.

Market Dynamics: Drivers & Restraints

Rising advancements in targeted therapies are significantly driving the gastric cancer treatment market growth

One of the most notable advancements in gastric cancer treatment has been the development of HER2-targeted therapies. HER2 (human epidermal growth factor receptor 2) is a protein overexpressed in some gastric cancer cells, leading to uncontrolled cell growth. Trastuzumab (Herceptin), a monoclonal antibody targeting HER2, has been a groundbreaking treatment for HER2-positive gastric cancer. The success of this treatment has led to its widespread use in combination with chemotherapy for advanced gastric cancer.

For instance, in October 2024, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) approved VYLOY (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test. VYLOY is the first and only CLDN18.2-targeted therapy approved in the U.S.

The rising advancements in targeted therapies have been a significant driver for the growth of the gastric cancer treatment market. The shift towards more personalized and effective treatments, combined with the FDA approvals of new drugs, the growing market acceptance, and the increased survival rates in patients, all contribute to this growth. As the research in this field continues to progress, it is expected that targeted therapies will become even more refined, offering greater hope for gastric cancer patients and expanding the market further.

Side effects and safety concerns associated with the treatment are hampering the market growth

Despite the significant advancements in gastric cancer treatment, side effects and safety concerns continue to pose major challenges in the management of the disease. The adverse effects associated with both traditional and targeted therapies often deter patients from adhering to prescribed regimens, impact their quality of life, and complicate treatment regimens. These concerns, in turn, hinder the widespread adoption and growth of the gastric cancer treatment market.

Chemotherapy remains a cornerstone of treatment for gastric cancer, but it is associated with a range of severe side effects. These can lead to dose reductions, discontinuation of therapy, and decreased quality of life, which ultimately hampers market growth. While targeted therapies and immunotherapies have revolutionized gastric cancer treatment, these therapies are not without their risks. Although they tend to have fewer side effects than chemotherapy, they can still cause severe immune-related adverse events (irAEs) or off-target effects.

Epidemiology Analysis

The incidence of gastric cancer is rising. As per DataM intelligence estimates, nearly 1.02 million prevalent cases are estimated worldwide in 2024. The region with the highest prevalence is the Asia-Pacific, accounting for 190.28 million cases. Early detection through screening, better treatment options, and improved public health measures have contributed to the decline in incidence and mortality rates in developed countries. However, gastric cancer continues to present a major healthcare burden, particularly in developing nations and among high-risk populations.

Segment Analysis

The global gastric cancer treatment market is segmented based on cancer type, treatment type, route of administration, and region.

Treatment Type:

The chemotherapy segment is expected to dominate the gastric cancer treatment market with the highest market share

Chemotherapy is frequently used as the primary treatment in advanced gastric cancer, often in combination with targeted therapies or immunotherapy. In cases where surgery is not possible, chemotherapy serves as a crucial palliative treatment to control symptoms, slow the disease's progression, and improve survival rates. For instance, FOLFOX (a combination of 5-fluorouracil (5-FU), oxaliplatin, and leucovorin) is a standard chemotherapy regimen used in gastric cancer. This regimen is particularly effective for advanced gastric cancer and has been widely adopted.

Chemotherapy is frequently combined with targeted therapies like trastuzumab, ramucirumab, and nivolumab to enhance efficacy, especially in advanced or metastatic gastric cancer. These combination regimens have become the standard of care in many treatment protocols. The growing trend of combining chemotherapy with newer therapies has expanded its market dominance, as it remains the central component of first-line and second-line treatment regimens in both HER2-positive and HER2-negative gastric cancers.

Geographical Analysis

North America is expected to hold a significant position in the global gastric cancer treatment market with the highest market share

The FDA (U.S. Food and Drug Administration) and Health Canada are at the forefront of regulatory approvals for new cancer therapies, including those for gastric cancer. These agencies have fast-tracked and drug approvals for novel treatments like TEVIMBRA (tislelizumab-jsgr), nivolumab (Opdivo), trastuzumab (Herceptin), and ramucirumab (Cyramza). This further accelerates the market growth in the region with various effective treatments.

For instance, in December 2024, BeiGene, Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administration (FDA) approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (>=1).

North America has been a leader in adopting targeted therapies and immunotherapies, which are increasingly used to treat gastric cancer. The region's healthcare system supports the use of expensive, but highly effective, biologics and immunotherapy drugs that target specific proteins or immune checkpoints involved in cancer progression. For instance, Trastuzumab (Herceptin) is widely used for HER2-positive gastric cancer, and its combination with chemotherapy has led to better survival rates. Nivolumab (Opdivo), an immune checkpoint inhibitor, is also approved for use in gastric cancer and has been shown to significantly improve survival in combination with chemotherapy.

Competitive Landscape

Top companies in the gastric cancer treatment market include Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC., and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global gastric cancer treatment market report delivers a detailed analysis with 68 key tables, more than 61 visually impactful figures and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.